The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The potential benefit of trastuzumab-based therapy upon lapatinib progression in heavily preatreated patients with advanced HER2 positive breast cancer.
Anastasios L. Boutis
No relevant relationships to disclose
Sofia Chatzileontiadou
No relevant relationships to disclose
Nikolaos Diamantopoulos
No relevant relationships to disclose
Athanasios Pouptsis
No relevant relationships to disclose
Chariklia Fotiou
No relevant relationships to disclose